Should you "just say 'no'"?

Stephen B Hanauer and Julie Solomon

doi:10.1038/ncpgasthep0058 | Full Text | PDF (62K)

Is the use of COX-2 inhibitors in gastroenterology cost-effective?

David Y Graham and Francis KL Chan

doi:10.1038/ncpgasthep0043 | Full Text | PDF (109K)

Can NOD2/CARD15 mutations predict intestinal graft-versus-host disease and aid our understanding of Crohn's disease?

Gerhard Rogler and Ernst Holler

doi:10.1038/ncpgasthep0042 | Full Text | PDF (113K)

Health-related quality of life in IBS

doi:10.1038/ncpgasthep0052 | Full Text | PDF (56K)

Live donor liver transplantation: graft and patient survival

doi:10.1038/ncpgasthep0053 | Full Text | PDF (56K)

Extrahepatic bile duct carcinoma without jaundice

doi:10.1038/ncpgasthep0054 | Full Text | PDF (73K)

Preventing acute rejection in pediatric liver transplantation

doi:10.1038/ncpgasthep0033 | Full Text | PDF (54K)

Tegaserod for chronic constipation

doi:10.1038/ncpgasthep0034 | Full Text | PDF (77K)

Valdecoxib reduces upper gastrointestinal ulcer complications

doi:10.1038/ncpgasthep0035 | Full Text | PDF (59K)

HCV recurrence after liver transplantation

doi:10.1038/ncpgasthep0046 | Full Text | PDF (59K)

Celiac disease: malignancy and mortality

doi:10.1038/ncpgasthep0036 | Full Text | PDF (55K)

Adenoma miss rate in optical colonoscopy

doi:10.1038/ncpgasthep0045 | Full Text | PDF (55K)

Avoiding false positives in H. pylori detection

doi:10.1038/ncpgasthep0047 | Full Text | PDF (78K)

Crohn's disease: new evidence of mycobacterial involvement

doi:10.1038/ncpgasthep0040 | Full Text | PDF (60K)

High-dose imatinib in metastatic GIST

doi:10.1038/ncpgasthep0041 | Full Text | PDF (60K)

Surgical practice patterns in stage IV colorectal cancer

doi:10.1038/ncponc0028 | Full Text | PDF (53K)

Single-agent cyclophosphamide in hepatoblastoma

doi:10.1038/ncponc0038 | Full Text | PDF (53K)

Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?

John McHutchison and Amany Zekry

doi:10.1038/ncpgasthep0050 | Full Text | PDF (108K)

Can the addition of bevacizumab to IFL chemotherapy improve outcome in colorectal cancer?

Eric Van Cutsem

doi:10.1038/ncpgasthep0051 | Full Text | PDF (101K)

Are miniature ultrasonic probes of clinical value for diagnosis and treatment of digestive tract diseases?

Vanessa M Shami

doi:10.1038/ncpgasthep0049 | Full Text | PDF (102K)

Long-term outcome improvement in patients with chronic hepatitis D treated with interferon

Vlad Ratziu and Thierry Poynard

doi:10.1038/ncpgasthep0044 | Full Text | PDF (96K)

Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?

Andrew Burroughs and Dimitrios Samonakis

doi:10.1038/ncpgasthep0038 | Full Text | PDF (105K)

Maintenance therapy versus episodic therapy with infliximab for Crohn's disease

Subrata Ghosh

doi:10.1038/ncpgasthep0039 | Full Text | PDF (90K)

Treating chronic anal fissure with botulinum neurotoxin

Giuseppe Brisinda, Federica Cadeddu, Francesco Brandara, Donatella Brisinda and Giorgio Maria

doi:10.1038/ncpgasthep0048 | Full Text | PDF (317K)

Drug Insight: nucleoside and nucleotide analog inhibitors for hepatitis B

Scott K Fung and Anna SF Lok

doi:10.1038/ncpgasthep0056 | Full Text | PDF (851K)

Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications

Scott L Friedman

doi:10.1038/ncpgasthep0055 | Full Text | PDF (361K)

Mechanisms of Disease: carcinogenesis in Barrett's esophagus

Navtej S Buttar and Kenneth K Wang

doi:10.1038/ncpgasthep0057 | Full Text | PDF (431K)